Expertise: Alignment of Organizational Goals, Objectives, and Execution
When studying processes within organizations, we commonly discover that there are mismatches among organizational goals, objectives and execution systems. Our expertise is in finding and eliminating such “barnacles” in systems, in realigning current systems to achieve organizational mandates, and in demonstrating how performance improves in aligned organizations.
Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
Khamalah J and Dilts DM (2001) “Determining Resource Needs for Specialty Ambulatory Clinics using Classification/Assignment Methods,” Int J of Operations and Quantitative Management, 7(4): 241-256.
Hill T, Menda R, and Dilts DM. (1998) “Using Product Profiling to Illustrate Manufacturing-Marketing Misalignment,” Interfaces, 28(4): 47-63.
Other Work Related to Alignment of Organizational Goals, Objectives, and Execution
1. Parker C, Snyder R, Jefford M, Dilts DM, Wolfe R, Millar J (2017) “A Randomized Control Trial of an Additional Funding Intervention to Improve Clinical Trial Enrollment”, J of the National Comprehensive Cancer Network (JNCCN),15(9): 1104-1110. PMID: 28874595
2. Massett, H, Dilts DM, Bailey R, Berktold J, Ledsky R, Atkinson (2017) “Raising Public Awareness of Clinical Trials: Development of Messages for a National Health Communication Campaign,” ˆJ of Health Communications 22(5):373-385. PMID:28339327
3. Stephenson D, (plus 14 others) (2015) Charting a path toward combination therapy for Alzheimer’s disease,” Expert Review of Neurotherapeutics, 15(1):107-13. PMID: 25540951
4. Massett H, Parreco LK, Padberg RM, Richmond ES, Rienzo, ME, Ryan Leonard CE, Quesenbery W, Killam HW, Johnson, and Dilts DM (2011) “AccrualNet: Addressing low accrual via a knowledge-based, community of practice Platform,” J of Oncology Practice, 7(6): e32-e39. PMID:22379429.
5. Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
6. Dilts DM, Ridner, SH, Franco A, Murphy B, (2009) “Patients with Cancer and E-mail: Implications for Clinical Communication,” J of Supportive Care in Cancer, 17(8): 1049-1056. PMID:19050941.
7. Khamalah J and Dilts DM (2001) “Determining Resource Needs for Specialty Ambulatory Clinics using Classification/Assignment Methods,” Int J of Operations and Quantitative Management, 7(4): 241-256.
8. Dilts DM (2001) “Functional Manager’s Perceptions of Performance Measurements: The Impact of Industry and Firm Level Characteristics,” Int J of Agile Manufacturing, 4(1): 17-28.
9. Dilts DM and Khamalah J (1999) “A comparison of ordinal analysis techniques in medical resource usage research,” Electronic Notes in Discrete Mathematics. (http://www.elsevier.com/cas/tree/store/ disc/sub/endm/store/disc2/disc2005.ps) (invited), 2: 51-68
10. Hill T, Menda R, and Dilts DM. (1998) “Using Product Profiling to Illustrate Manufacturing-Marketing Misalignment,” Interfaces, 28(4): 47-63.
11. Menda, R, and Dilts DM, (1997) “The Manufacturing Strategy Formulation Process: Linking Multifunctional Viewpoints,” J of Operations Management, 15(4): 223-41.
12. Doughty MJ, Dilts DM, and Lyle, WM, (1996) “Impact of Using Weighted Versus Unweighted Measures for Assessments of Optometry Faculty Productivity in Research,” J of the Am Optometric Association, 67(7): 410-420. PMID: 8888867
13. Khamalah J, Dilts DM, and Plotkin AD, (1995) “Using Cluster Analysis For Medical Resource Decision Making,” Medical Decision Making, 15(4, Oct-Dec): 333-347. PMID: 8544677
14. Dilts DM, Khamalah J, and Plotkin AD, (1994) “Clinical Low Vision Resource Usage Prediction,” Optometry & Vision Science, 71(7): 422-436. PMID: 7970557
15. Dilts DM (1994) “Teaching Interfirm Relationships: The Supply Chain Game,” Operations Management Review, 10(3): 81-87. (invited)
16. Yee, D, (34 others) (2012) “Adaptive trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development,” J of Clin Onc, Letter, Dec 20; 30(36): 4584-6. doi: 10.1200/JCO.2012.44.1022
17. Cheney A, Pence K, and Dilts DM, (2014) “Organizational Impacts of Participation in Development of Industry-Level Technology Roadmaps,” 4th IAJC/ISAM Conference Proceedings, Sept, Orlando, FL. http://cd14.ijme.us/itc/
18. Dilts DM (2014) “Time has come to raise the bar in oncology clinical trials,” J Clin Onc, 30, PMID:22454422 doi: 10.1200/JCO.2013.53.8009
19. Cheng S and Dilts DM (2013) “Building Expertise in The Translational Processes Through Partnerships with Schools of Business” book chapter in Translational Research in Biomedicine, Karger Publishing DOI: 10.1159/000343022
20. Dilts DM, Cheng SK (2012) “The Importance of Doing Trials Right While Doing The Right Trials,” Clin Cancer Res, 18(1):3-5. PMID:22072734
21. Blajchman MA, Glynn SA, Josephson CD, Kleinman SH (2010) “Clinical Trial Opportunities in Transfusion Medicine: Proceedings of an NHLBI State of the Science Symposium,” role: contributor, Transfusion Medicine Reviews, 24(4): 259-85. PMID: 20851330
22. King A, Earnest J, Lembach J, Lycette J, Kelleher C, Dilts DM (2010) “Axis Definitions for CTSA Portfolio Analysis ,” National Center for Research Resources (NCRR), Evaluation Key Function Meeting, Bethesda MD (Dec)
23. King A, Earnest J, Lembach J, Lycette J, Kelleher C, Dilts DM (2010) “Evaluation Key Function Committee December 2010 Meeting,” National Center for Research Resources (NCRR), Evaluation Key Function Meeting, Bethesda MD (Dec)
24. Cheng S, Dietrich, M, Finnigan S, Dilts DM (2010) “Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials” J Clin Oncol 28:15s (suppl; abstr 6001)
25. Dilts DM and Pence, Ken (2007) “The Decision to Fail: An Exploratory Study of Terminated Technical Projects,” Academy of Management Meeting, Philadelphia PA, best paper competition presentation for the Journal of Operations Management
26. Ferranti, L and Dilts DM (2005) “A Review of Medical Registries and Outcomes: Potential Use for Real-Time Improvement in Patient Safety: The Dearth of Real-Time Science-Based Medicine,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
27. Xie, Bin and Dilts DM (2005) “Effects of Patient Obtained Medical Information (POMI) on Healthcare Services Utilization in U.S. Counties,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
28. Inukai, Tsuyshi and Dilts DM (2004) “The Impact of Technological Innovation Type on Strategic Alliances for New Product Development,” Academy of Management National Conference.
29. (2014) “Understanding the linkages among mission, processes and metrics in running a core”, Keynote address, Midwest & Southeast Association of Biomolecular Resource Facilities 2014 Annual Meeting, Nashville TN(Oct).
30. (2014) “The Promise and Perils in Clinical Trials,” Monash University, Melbourne, Australia(August, presented twice)
31. (2014) “Observations on Cancer Research from a Non-Medical Researcher,” keynote speech, Cancer Institute of New South Wales Annual Awards Banquet(August)
32. (2014) “The Importance of Doing Trials Right While doing the Right Trials,” Ministry of Health, NSW, Australia(August)
33. (2014) “Overcoming the Barriers of Transparency in Clinical Trial Data Access,” ASCO National Meeting, Chicago IL(June)
34. (2014) “Integration Metrics: Linking Mission, Science, Resources and Education,” NICHD Division of Intramural Research, Scientific Retreat, Bethesda, MD(Feb).
35. (2013) “Prioritizing and Measuring Clinical Research,” NIH Clinical Research Subcommittee, Bethesda, MD(Sept).
36. (2013) “Cooperative Groups, Version 3.0”, Palliative Care Research Consortium meeting, Chicago, IL(Sept).
37. (2013) “Consortium or not to Consortium”, ACT-AD National Meeting on Alzheimer’s Research, Washington, DC(May)
38. (2013) “A Model for Evaluating the Efficiency and Effectiveness of Clinical Research,” Medical Executive Committee, NIH, Bethesda MD(May).
39. (2013) “Process Improvement: Linking Improvement to Strategy,” Oregon Health Financial Manager’s Association, Portland, OR(Feb)
40. (2012) “Precompetitive Collaboration & Coopetition: Lessons Learned from History and Other Industries,” ACT-AD annual meeting, Bethesda MD(Nov)
41. (2012) “Metrics for Clinical Trials: Lessons Learned”, CTSA Annual Evaluation Meeting, Bethesda MD(Oct)
42. (2011) “Management Principles in Healthcare” Southern Health, Melbourne AUS(Nov) and The Albert Hospital System, Melbourne AUS(Nov)
43. (2011) “Multi-disciplinary, Useful research” Melbourne Operations Management Society(MOMS)(Nov)
44. (2011) “Process Mapping – Purpose, Method & Expected Results,” University of Cincinnati Academic Health Center, Center for Clinical & Translational Science & Training(Sept)
45. (2011) “Precompetitive Collaboration: Lessons from History and Other Industries,” UCSF Accelerating Targeted Cancer Drug-Biomarker Development Conference, San Francisco CA(May)
46. (2011) “Mis-Measurement of Quality in IRBs: Thoughts from Other Industries,” 13th annual Subject Protection conference, Schulman Group, Cincinnati Children’s and the University of Kentucky, Cincinnati, OH(Sept).
47. (2010) “Beyond Efficiency: A Strategic Approach to Clinical Research,” Keynote address, 10th Annual Oncore Users Group Madison, WI(Aug)
48. (2010) “The Science of Trial Selection, Infrastructure, and Operations,” NCI-ASCO Symposium on Accruals, Chicago IL(Apr)
49. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
50. (2009) “Envisioning the Future: Roadmaps & Roadmapping” keynote address to Radiological Society of North America QIBA Roadmapping committee, Chicago IL(Mar)
51. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)
52. (2008) “Building Networks: Observations from Oncology and Non-Medical Industries”, keynote address for the NHLBI Workshop on Sickle Cell Disease. Washington, DC(Oct)
53. CCR Strategy Development
54. CCR Organizational Redesign
55. NICHD Intramural Program Organizational Redesing
56. COG Orgranizational Redesign
57. Behringer B, Omohundro E, Boswell D, Evans D and Ferranti L. The Tennessee Department of Health WORKshops on the Use of Secondary Data for Community Health Assessment, 2012. Preventing Chronic Disease. (2014). 11:130206. DOI: http://dx.doi.org/10.5888/pdc.11.130260.
2. Massett, H, Dilts DM, Bailey R, Berktold J, Ledsky R, Atkinson (2017) “Raising Public Awareness of Clinical Trials: Development of Messages for a National Health Communication Campaign,” ˆJ of Health Communications 22(5):373-385. PMID:28339327
3. Stephenson D, (plus 14 others) (2015) Charting a path toward combination therapy for Alzheimer’s disease,” Expert Review of Neurotherapeutics, 15(1):107-13. PMID: 25540951
4. Massett H, Parreco LK, Padberg RM, Richmond ES, Rienzo, ME, Ryan Leonard CE, Quesenbery W, Killam HW, Johnson, and Dilts DM (2011) “AccrualNet: Addressing low accrual via a knowledge-based, community of practice Platform,” J of Oncology Practice, 7(6): e32-e39. PMID:22379429.
5. Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
6. Dilts DM, Ridner, SH, Franco A, Murphy B, (2009) “Patients with Cancer and E-mail: Implications for Clinical Communication,” J of Supportive Care in Cancer, 17(8): 1049-1056. PMID:19050941.
7. Khamalah J and Dilts DM (2001) “Determining Resource Needs for Specialty Ambulatory Clinics using Classification/Assignment Methods,” Int J of Operations and Quantitative Management, 7(4): 241-256.
8. Dilts DM (2001) “Functional Manager’s Perceptions of Performance Measurements: The Impact of Industry and Firm Level Characteristics,” Int J of Agile Manufacturing, 4(1): 17-28.
9. Dilts DM and Khamalah J (1999) “A comparison of ordinal analysis techniques in medical resource usage research,” Electronic Notes in Discrete Mathematics. (http://www.elsevier.com/cas/tree/store/ disc/sub/endm/store/disc2/disc2005.ps) (invited), 2: 51-68
10. Hill T, Menda R, and Dilts DM. (1998) “Using Product Profiling to Illustrate Manufacturing-Marketing Misalignment,” Interfaces, 28(4): 47-63.
11. Menda, R, and Dilts DM, (1997) “The Manufacturing Strategy Formulation Process: Linking Multifunctional Viewpoints,” J of Operations Management, 15(4): 223-41.
12. Doughty MJ, Dilts DM, and Lyle, WM, (1996) “Impact of Using Weighted Versus Unweighted Measures for Assessments of Optometry Faculty Productivity in Research,” J of the Am Optometric Association, 67(7): 410-420. PMID: 8888867
13. Khamalah J, Dilts DM, and Plotkin AD, (1995) “Using Cluster Analysis For Medical Resource Decision Making,” Medical Decision Making, 15(4, Oct-Dec): 333-347. PMID: 8544677
14. Dilts DM, Khamalah J, and Plotkin AD, (1994) “Clinical Low Vision Resource Usage Prediction,” Optometry & Vision Science, 71(7): 422-436. PMID: 7970557
15. Dilts DM (1994) “Teaching Interfirm Relationships: The Supply Chain Game,” Operations Management Review, 10(3): 81-87. (invited)
16. Yee, D, (34 others) (2012) “Adaptive trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development,” J of Clin Onc, Letter, Dec 20; 30(36): 4584-6. doi: 10.1200/JCO.2012.44.1022
17. Cheney A, Pence K, and Dilts DM, (2014) “Organizational Impacts of Participation in Development of Industry-Level Technology Roadmaps,” 4th IAJC/ISAM Conference Proceedings, Sept, Orlando, FL. http://cd14.ijme.us/itc/
18. Dilts DM (2014) “Time has come to raise the bar in oncology clinical trials,” J Clin Onc, 30, PMID:22454422 doi: 10.1200/JCO.2013.53.8009
19. Cheng S and Dilts DM (2013) “Building Expertise in The Translational Processes Through Partnerships with Schools of Business” book chapter in Translational Research in Biomedicine, Karger Publishing DOI: 10.1159/000343022
20. Dilts DM, Cheng SK (2012) “The Importance of Doing Trials Right While Doing The Right Trials,” Clin Cancer Res, 18(1):3-5. PMID:22072734
21. Blajchman MA, Glynn SA, Josephson CD, Kleinman SH (2010) “Clinical Trial Opportunities in Transfusion Medicine: Proceedings of an NHLBI State of the Science Symposium,” role: contributor, Transfusion Medicine Reviews, 24(4): 259-85. PMID: 20851330
22. King A, Earnest J, Lembach J, Lycette J, Kelleher C, Dilts DM (2010) “Axis Definitions for CTSA Portfolio Analysis ,” National Center for Research Resources (NCRR), Evaluation Key Function Meeting, Bethesda MD (Dec)
23. King A, Earnest J, Lembach J, Lycette J, Kelleher C, Dilts DM (2010) “Evaluation Key Function Committee December 2010 Meeting,” National Center for Research Resources (NCRR), Evaluation Key Function Meeting, Bethesda MD (Dec)
24. Cheng S, Dietrich, M, Finnigan S, Dilts DM (2010) “Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials” J Clin Oncol 28:15s (suppl; abstr 6001)
25. Dilts DM and Pence, Ken (2007) “The Decision to Fail: An Exploratory Study of Terminated Technical Projects,” Academy of Management Meeting, Philadelphia PA, best paper competition presentation for the Journal of Operations Management
26. Ferranti, L and Dilts DM (2005) “A Review of Medical Registries and Outcomes: Potential Use for Real-Time Improvement in Patient Safety: The Dearth of Real-Time Science-Based Medicine,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
27. Xie, Bin and Dilts DM (2005) “Effects of Patient Obtained Medical Information (POMI) on Healthcare Services Utilization in U.S. Counties,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
28. Inukai, Tsuyshi and Dilts DM (2004) “The Impact of Technological Innovation Type on Strategic Alliances for New Product Development,” Academy of Management National Conference.
29. (2014) “Understanding the linkages among mission, processes and metrics in running a core”, Keynote address, Midwest & Southeast Association of Biomolecular Resource Facilities 2014 Annual Meeting, Nashville TN(Oct).
30. (2014) “The Promise and Perils in Clinical Trials,” Monash University, Melbourne, Australia(August, presented twice)
31. (2014) “Observations on Cancer Research from a Non-Medical Researcher,” keynote speech, Cancer Institute of New South Wales Annual Awards Banquet(August)
32. (2014) “The Importance of Doing Trials Right While doing the Right Trials,” Ministry of Health, NSW, Australia(August)
33. (2014) “Overcoming the Barriers of Transparency in Clinical Trial Data Access,” ASCO National Meeting, Chicago IL(June)
34. (2014) “Integration Metrics: Linking Mission, Science, Resources and Education,” NICHD Division of Intramural Research, Scientific Retreat, Bethesda, MD(Feb).
35. (2013) “Prioritizing and Measuring Clinical Research,” NIH Clinical Research Subcommittee, Bethesda, MD(Sept).
36. (2013) “Cooperative Groups, Version 3.0”, Palliative Care Research Consortium meeting, Chicago, IL(Sept).
37. (2013) “Consortium or not to Consortium”, ACT-AD National Meeting on Alzheimer’s Research, Washington, DC(May)
38. (2013) “A Model for Evaluating the Efficiency and Effectiveness of Clinical Research,” Medical Executive Committee, NIH, Bethesda MD(May).
39. (2013) “Process Improvement: Linking Improvement to Strategy,” Oregon Health Financial Manager’s Association, Portland, OR(Feb)
40. (2012) “Precompetitive Collaboration & Coopetition: Lessons Learned from History and Other Industries,” ACT-AD annual meeting, Bethesda MD(Nov)
41. (2012) “Metrics for Clinical Trials: Lessons Learned”, CTSA Annual Evaluation Meeting, Bethesda MD(Oct)
42. (2011) “Management Principles in Healthcare” Southern Health, Melbourne AUS(Nov) and The Albert Hospital System, Melbourne AUS(Nov)
43. (2011) “Multi-disciplinary, Useful research” Melbourne Operations Management Society(MOMS)(Nov)
44. (2011) “Process Mapping – Purpose, Method & Expected Results,” University of Cincinnati Academic Health Center, Center for Clinical & Translational Science & Training(Sept)
45. (2011) “Precompetitive Collaboration: Lessons from History and Other Industries,” UCSF Accelerating Targeted Cancer Drug-Biomarker Development Conference, San Francisco CA(May)
46. (2011) “Mis-Measurement of Quality in IRBs: Thoughts from Other Industries,” 13th annual Subject Protection conference, Schulman Group, Cincinnati Children’s and the University of Kentucky, Cincinnati, OH(Sept).
47. (2010) “Beyond Efficiency: A Strategic Approach to Clinical Research,” Keynote address, 10th Annual Oncore Users Group Madison, WI(Aug)
48. (2010) “The Science of Trial Selection, Infrastructure, and Operations,” NCI-ASCO Symposium on Accruals, Chicago IL(Apr)
49. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
50. (2009) “Envisioning the Future: Roadmaps & Roadmapping” keynote address to Radiological Society of North America QIBA Roadmapping committee, Chicago IL(Mar)
51. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)
52. (2008) “Building Networks: Observations from Oncology and Non-Medical Industries”, keynote address for the NHLBI Workshop on Sickle Cell Disease. Washington, DC(Oct)
53. CCR Strategy Development
54. CCR Organizational Redesign
55. NICHD Intramural Program Organizational Redesing
56. COG Orgranizational Redesign
57. Behringer B, Omohundro E, Boswell D, Evans D and Ferranti L. The Tennessee Department of Health WORKshops on the Use of Secondary Data for Community Health Assessment, 2012. Preventing Chronic Disease. (2014). 11:130206. DOI: http://dx.doi.org/10.5888/pdc.11.130260.